AstraZeneca Submits SNDA For SEROQUEL(R) For Bipolar Depression Treatment
Sunday, November 30th, 2008“AstraZeneca be faithful to rising patients’ before a live audience and surfacing contemporary treatment all for psychosomatic illness,” said Wayne Macfadden, MD, US Medical Director for SEROQUEL. “This sNDA submission is an astonishing milestone within the ahead of time period of SEROQUEL. If SEROQUEL receive approbation from the FDA to immoderation bipolar disquiet, […]

